{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:16:36Z","timestamp":1791591396597,"version":"4.3.4"},"reference-count":52,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Herbal Institute R&amp;D in Vallberga","award":["Nr 2021-2"],"award-info":[{"award-number":["Nr 2021-2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Currently, no effective treatment of comorbid complications or COVID-19 long-haulers during convalescence is known. This randomized, quadruple-blind, placebo-controlled trial aimed to assess the efficacy of adaptogens on the recovery of patients with Long COVID symptoms. One hundred patients with confirmed positive SARS-CoV-2 test, discharged from COVID Hotel isolation, Intensive Care Unit (ICU), or Online Clinics, and who experienced at least three of nine Long COVID symptoms (fatigue, headache, respiratory insufficiency, cognitive performance, mood disorders, loss of smell, taste, and hair, sweatiness, cough, pain in joints, muscles, and chest) in the 30 days before randomization were included in the study of the efficacy of Chisan\u00ae\/ADAPT-232 (a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra) supplementation for two weeks. Chisan\u00ae decreased the duration of fatigue and pain for one and two days, respectively, in 50% of patients. The number of patients with lack of fatigue and pain symptoms was significantly less in the Chisan\u00ae treatment group than in the placebo group on Days 9 (39% vs. 57%, pain relief, p = 0.0019) and 11 (28% vs. 43%, relief of fatigue, * p = 0.0157). Significant relief of severity of all Long COVID symptoms over the time of treatment and the follow-up period was observed in both groups of patients, notably decreasing the level of anxiety and depression from mild and moderate to normal, as well as increasing cognitive performance in patients in the d2 test for attention and increasing their physical activity and workout (daily walk time). However, the significant difference between placebo and Chisan\u00ae treatment was observed only with a workout (daily walk time) and relieving respiratory insufficiency (cough). A clinical assessment of blood markers of the inflammatory response (C-reactive protein) and blood coagulation (D-dimer) did not reveal any significant difference over time between treatment groups except significantly lower IL-6 in the Chisan\u00ae treatment group. Furthermore, a significant difference between the placebo and Chisan\u00ae treatment was observed for creatinine: Chisan\u00ae significantly decreased blood creatinine compared to the placebo, suggesting prevention of renal failure progression in Long COVID. In this study, we, for the first time, demonstrate that adaptogens can increase physical performance in Long COVID and reduce the duration of fatigue and chronic pain. It also suggests that Chisan\u00ae\/ADAPT-232 might be useful for preventing the progression of renal failure associated with increasing creatinine.<\/jats:p>","DOI":"10.3390\/ph15030345","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T21:44:17Z","timestamp":1647207857000},"page":"345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial"],"prefix":"10.3390","volume":"15","author":[{"given":"Irina","family":"Karosanidze","sequence":"first","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ushangi","family":"Kiladze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Kirtadze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Giorgadze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Amashukeli","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Parulava","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neli","family":"Iluridze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kikabidze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Gudavadze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lali","family":"Gelashvili","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vazha","family":"Koberidze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eka","family":"Gigashvili","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natela","family":"Jajanidze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naira","family":"Latsabidze","sequence":"additional","affiliation":[{"name":"National Family Medicine Training Centre, 57 M. Tsinamdzghvrishvili Str., Tbilisi 0102, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nato","family":"Mamageishvili","sequence":"additional","affiliation":[{"name":"Department for History of Medicine and Bioethics, Faculty of Medicine, Tbilisi State Medical University, Vazha-Pshavela Ave. 33, Tbilisi 0162, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaz","family":"Shengelia","sequence":"additional","affiliation":[{"name":"Department for History of Medicine and Bioethics, Faculty of Medicine, Tbilisi State Medical University, Vazha-Pshavela Ave. 33, Tbilisi 0162, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areg","family":"Hovhannisyan","sequence":"additional","affiliation":[{"name":"Institute of Fine Organic Chemistry, National Academy of Science, Azatutian ave. 26, Yerevan 375014, Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-4525","authenticated-orcid":false,"given":"Alexander","family":"Panossian","sequence":"additional","affiliation":[{"name":"Phytomed AB, Bofinksvagen 1, 31275 V\u00e5xtorp, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100731","DOI":"10.1016\/j.eclinm.2021.100731","article-title":"Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach","volume":"32","author":"Antoni","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P.A., Cuapio, A., and Villapol, S. (2021). More than 50 Long-term effects of COVID-19: A systematic review and meta-analysis. medRxiv, Available online: https:\/\/www.nature.com\/articles\/s41598-021-95565-8.pdf.","DOI":"10.21203\/rs.3.rs-266574\/v1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.15585\/mmwr.mm6930e1","article-title":"CDC COVID-19 Response Team, IVY Network Investigators. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network\u2014United States, March\u2013June 2020","volume":"69","author":"Tenforde","year":"2020","journal-title":"MMWR Morb. Mort. Wkly. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113426","DOI":"10.1016\/j.socscimed.2020.113426","article-title":"How and why patients made Long COVID","volume":"268","author":"Callard","year":"2021","journal-title":"Soc. Sci. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"00542-2020","DOI":"10.1183\/23120541.00542-2020","article-title":"Persistent symptoms 3\u2005months after a SARS-CoV-2 infection: The post-COVID-19 syndrome?","volume":"6","author":"Delbressine","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2215-0366(20)30203-0","article-title":"Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic","volume":"7","author":"Rogers","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_7","unstructured":"ClinicalTrials.gov (2022, February 14). Long COVID, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?term=Long+COVID&cond=COVID-19&age_v=&gndr=&type=Intr&rslt=&Search=Apply."},{"key":"ref_8","unstructured":"ClinicalTrials.gov (2022, February 14). COVID-19 Long-Haulers Study, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04678830."},{"key":"ref_9","unstructured":"ClinicalTrials.gov (2022, February 14). Zilucoplan\u00ae in Improving Oxygenation and Short- and Long-Term Outcome of COVID-19 Patients with Acute Hypoxic Respiratory Failure, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04382755."},{"key":"ref_10","unstructured":"ClinicalTrials.gov (2022, February 14). WHO COVID-19\u2014Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05080244."},{"key":"ref_11","unstructured":"ClinicalTrials.gov (2022, February 14). Phase 2 Study of RSLV-132 in Subjects with Long COVID, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04944121."},{"key":"ref_12","unstructured":"ClinicalTrials.gov (2022, February 14). Homeopathic Treatment of Post-Acute COVID-19 Syndrome, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05104749."},{"key":"ref_13","unstructured":"ClinicalTrials.gov (2022, February 14). Feasibility of Cannabidiol for the Treatment of Long COVID, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04997395."},{"key":"ref_14","unstructured":"ClinicalTrials.gov (2022, February 14). Efficacy of Montelukast in Mild-Moderate Respiratory Symptoms in Patients with Long-COVID-19: (E-SPERANZA), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04695704."},{"key":"ref_15","unstructured":"ClinicalTrials.gov (2022, February 14). Pilot Study Into LDN and NAD+ for Treatment of Patients with Post-COVID-19 Syndrome, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04604704."},{"key":"ref_16","unstructured":"ClinicalTrials.gov (2022, February 14). Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post COVID-19 Recovery Among Health Care Workers, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05121766."},{"key":"ref_17","unstructured":"ClinicalTrials.gov (2022, February 14). HElping Alleviate the Longer-Term Consequences of COVID-19 (HEAL-COVID), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04801940."},{"key":"ref_18","unstructured":"ClinicalTrials.gov (2022, February 14). A Randomised-Controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04950803."},{"key":"ref_19","unstructured":"ClinicalTrials.gov (2022, February 14). COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04510194."},{"key":"ref_20","unstructured":"ClinicalTrials.gov (2022, February 14). LYT-100 in Post-Acute COVID-19 Respiratory Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04652518."},{"key":"ref_21","unstructured":"ClinicalTrials.gov (2022, February 14). Vortioxetine for Post-COVID-19 Syndrome, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05047952."},{"key":"ref_22","unstructured":"ClinicalTrials.gov (2022, February 14). Coenzyme Q10 as Treatment for Long Term COVID-19, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04960215."},{"key":"ref_23","unstructured":"ClinicalTrials.gov (2022, February 14). Special Chinese Medicine Out-Patient Programme for Discharged COVID-19 Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0444605."},{"key":"ref_24","unstructured":"ClinicalTrials.gov (2022, February 14). Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19 (SPIDEX-II), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04826822."},{"key":"ref_25","unstructured":"ClinicalTrials.gov (2022, February 14). The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients With Post-Acute COVID-19 Syndrome, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05150782."},{"key":"ref_26","unstructured":"ClinicalTrials.gov (2022, February 14). Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 (PEP-CQ), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04408456."},{"key":"ref_27","unstructured":"ClinicalTrials.gov (2022, February 14). CACOLAC: Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04404426."},{"key":"ref_28","unstructured":"ClinicalTrials.gov (2022, February 14). Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04846010."},{"key":"ref_29","unstructured":"ClinicalTrials.gov (2022, February 14). Efficacy, Safety, Tolerability of AXA1125 in Fatigue Predominant PASC, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05152849."},{"key":"ref_30","unstructured":"ClinicalTrials.gov (2022, February 14). Evaluation of the Effect of Long-Term Lipid-Lowering Therapy in STEMI Patients with Coronavirus Infection COVID-19, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04900155."},{"key":"ref_31","unstructured":"(2022, February 14). Post COVID-19 Syndrome and the Gut-Lung Axis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04813718."},{"key":"ref_32","unstructured":"ClinicalTrials.gov (2022, February 14). A Study of Immune System Proteins in Participants with Mild to Moderate COVID-19 Illness, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04634409."},{"key":"ref_33","unstructured":"ClinicalTrials.gov (2022, February 14). Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05055427."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11655-021-3328-3","article-title":"Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study","volume":"27","author":"Li","year":"2021","journal-title":"Chin. J. Integr. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108412","DOI":"10.1016\/j.intimp.2021.108412","article-title":"Levocetirizine and montelukast in the COVID-19 treatment paradigm","volume":"103","author":"May","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13063-021-05951-w","article-title":"Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol","volume":"23","author":"Cordero","year":"2022","journal-title":"Trials"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.phymed.2004.11.004","article-title":"Impact of Chisan (ADAPT-232) on the quality-of-life and its efficacy as an adjuvant in the treatment of acute non-specific pneumonia","volume":"12","author":"Narimanian","year":"2005","journal-title":"Phytomedicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.phymed.2010.02.005","article-title":"Double-blind, placebo-controlled, randomized study of the single-dose effects of ADAPT-232 on cognitive functions","volume":"17","author":"Aslanyan","year":"2010","journal-title":"Phytomedicine"},{"key":"ref_39","first-page":"2","article-title":"Efficacy of Adaptogenic Supplements on Adapting to Stress: A Randomized, Controlled Trial","volume":"19","author":"Hovhannisyan","year":"2015","journal-title":"J. Athl. Enhanc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/157488409789375311","article-title":"Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity","volume":"4","author":"Panossian","year":"2009","journal-title":"Current Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fnins.2013.00016","article-title":"Synergy and Antagonism of Active Constituents of ADAPT-232 on Transcriptional Level of Metabolic Regulation of Isolated Neuroglial Cells","volume":"7","author":"Panossian","year":"2013","journal-title":"Front. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Panossian, A., and Brendler, T. (2020). The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090236"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1002\/jmv.26654","article-title":"Defining IL-6 levels in healthy individuals: A meta-analysis","volume":"93","author":"Said","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12967-020-02571-x","article-title":"Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: A cohort study","volume":"18","author":"Zhang","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sabaka, P., Ko\u0161\u010d\u00e1lov\u00e1, A., Straka, I., Hodosy, J., Lipt\u00e1k, R., Kmotorkov\u00e1, B., Kachl\u00edkov\u00e1, M., and Ku\u0161n\u00edrov\u00e1, A. (2021). Role of interleukin 6 as a predictive factor for a severe course of COVID-19: Retrospective data analysis of patients from a long-term care facility during COVID-19 outbreak. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05945-8"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12931-020-01546-2","article-title":"Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients\u2019 performance: A prospective observational cohort study","volume":"21","author":"Sonnweber","year":"2020","journal-title":"Respir. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cione, E., Siniscalchi, A., Gangemi, P., Cosco, L., Colosimo, M., Longhini, F., Luciani, F., De Sarro, G., G&SPWorking Group Berrino, L., and D\u2019Agostino, B. (2021). Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251819"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1681\/ASN.2021060734","article-title":"Kidney Outcomes in Long COVID","volume":"32","author":"Bowe","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"G\u0142owacka, M., Lipka, S., M\u0142ynarska, E., Franczyk, B., and Rysz, J. (2021). Acute Kidney Injury in COVID-19. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158081"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41581-021-00487-3","article-title":"Long COVID and kidney disease","volume":"17","author":"Yende","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, N.H., Cheng, Y.C., Luo, R., Zhang, C.X., Ge, S.W., and Xu, G. (2021). Recovery of new-onset kidney disease in COVID-19 patients discharged from hospital. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06105-8"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/med.21743","article-title":"Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases","volume":"41","author":"Panossian","year":"2021","journal-title":"Med. Res. Rev."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/3\/345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:13Z","timestamp":1760135713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/3\/345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ph15030345"],"URL":"https:\/\/doi.org\/10.3390\/ph15030345","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}